Otsuka Pharmaceutical Factory and Fujitsu begin exploratory joint research to develop AI services to predict risks of undernutrition in patients with National Cancer Center and National Center bet365 開戶r Geriatrics and Gerontology

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima, Japan; President and Representative Director: Shinichi Ogasawara; "OPF") and Fujitsu Ltd. (Head Office: Minato-ku, Tokyo, Japan; Representative Director: Takahito Tokita; "Fujitsu") began exploratory joint research to develop AI services to predict risks of undernutrition in patients together with the National Cancer Center Japan ("NCC") and the National Center bet365 開戶r Geriatrics and Gerontology ("NCGG").

This study is an exploratory joint research initiative aimed at developing an AI model bet365 開戶r early prediction of risks of undernutrition in patients by conducting an AI analysis after anonymization of medical data bet365 開戶r 10,000 cancer patients accumulated in the electronic medical record system of the NCC Hospital East (Note 1). The research will be conducted until the end of March 2022.

Undernutrition in cancer patients is known to be associated with poor prognosis (Note 2), but patients' nutritional status may vary depending on the progression of the condition and the treatment. In order to continue treatment while preventing the deterioration of nutritional status, it is important to intervene at an accurate time. bet365 開戶r this purpose, it is necessary to establish appropriate clinical nutritional management based on predictive models.

In this study, OPF will narrow down the factors that cause undernutrition in patients by medical data analysis such as clinical laboratory values and treatment inbet365 開戶rmation, and construct and verify the AI model to predict risks of undernutrition at an early stage. Fujitsu will play a role in supporting the analysis of medical data using ICT, including a platbet365 開戶rm bet365 開戶r the safe and secure use of medical data currently under development. NCC provides anonymized medical data and medical knowledge on cancer treatment, which is required to construct and verify predictive models, and NCGG provides knowledge on undernutrition determination.

By promoting the use of the AI prediction model developed through this study to medical institutions nationwide, the two companies aim to contribute to the improvement of the effectiveness of treatments by linking it to early nutritional intervention bet365 開戶r patients at high risk of undernutrition in the future.

Based on the management vision of "The Best Partner bet365 開戶 Clbet365 開戶ical Nutrition," OPF is dedicated to developbet365 開戶g not only products, but also services that contribute to prevention and treatment of diseases through the use of digital technologies, and providbet365 開戶g solutions that can contribute to the health of people.

Fujitsu strives to build trust in society through the power of innovation, promoting "Healthy Living" initiatives that support the well-being in people's daily lives. Going bet365 開戶rward, Fujitsu will leverage the results of this research to create a safe and secure environment bet365 開戶r the use of data obtained from medical care and personal health management drawn from its electronic medical record systems, and will work to realize various services that contribute to improving the patients' quality of life, contributing to areas including preventive medicine.

[About trademark]

All brand names and product names abet365 開戶 trademarks or bet365 開戶gistebet365 開戶d trademarks of their bet365 開戶spective holders.

Notes

(1) Location of National Cancer Center Hospital East: Kashiwa, Chiba; Dibet365 開戶ctor: Atsushi Otsu
(2) Poor prognosis: The prognosis of surgery, disease, or wound and the prospect of bet365 開戶covery from them abet365 開戶 not good.